$116.3 Million

IO Biotech, Inc.

Initial Public Offering

Bookrunner, November 2021

IO Biotech, Inc. (the “Company”) is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies. The Company’s T-win platform is designed to activate naturally occurring T-cells to target immunosuppressive mechanisms.  The Company’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as Indoleamine 2,3-dehydrogenase (IDO) and programmed death ligand (PD-L1).

More Like This

Mar 2022
$79.4 Million

Initial Public Offering

Lead Left Bookrunner

View Details
Nov 2021
$500.3 Million

Initial Public Offering

Bookrunner

View Details
Oct 2021
$86.9 Million

Initial Public Offering

Lead Left Bookrunner

View Details